Products for Research Use Only
RegisterLogin

Londamocitinib

CAT: 0804-HY-126294-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-126294-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Londamocitinib (AZD4604) is a potent and selective JAK1 inhibitor with IC50 at 0.54 nM. Londamocitinib has anti-inflammatory activity[1][2][3].
CAS Number
2241039-81-4
Product Name Alternative
AZD4604; JAK1-IN-7
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
JAK
Type
Reference compound
Related Pathways
Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/londamocitinib.html
Purity
99.79
Solubility
DMSO : 71.43 mg/mL (ultrasonic)
Smiles
FC1=C(S(C)(=O)=O)C=CC=C1NC2=NC(C3=CNC4=C3C=CC=C4NC([C@@H](COC)N5CCN(C)CC5)=O)=C(F)C=N2
Molecular Formula
C28H31F2N7O4S
Molecular Weight
599.65
Precautions
H302, H315, H319, H335
References & Citations
[1]NILSSON, Karl, Magnus, et al. Jak1 selective inhibitors. WO2018134213A1.|[2]Nilsson M, et al. Discovery of the Potent and Selective Inhaled Janus Kinase 1 Inhibitor AZD4604 and Its Preclinical Characterization. J Med Chem. 2023 Oct 12;66 (19) :13400-13415.|[3]Nilsson M, et al. Characterization of Selective and Potent JAK1 Inhibitors Intended for the Inhaled Treatment of Asthma. Drug Des Devel Ther. 2022 Aug 31;16:2901-2917.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
JAK1

Alternative Products

CatalogName
M32971-01Londamocitinib

Popular Products